Valeant Pharma (NYSE: VRX) reported Q2 EPS of ($0.11), versus ($0.88) reported last year. Revenue for the quarter came in at $2.23 billion, versus $2.42 billion reported last year.

Adjusted EBITDA (non-GAAP) Sequential Increase of 10% to $951 million, beating consensus of $910.8 million.

Second-Quarter 2017 Financial Results

• Revenues of $2.233 Billion
• GAAP Net Loss of $38 Million
• Adjusted Net Income (non-GAAP) of $362 Million
• Year-to-Date GAAP Cash Flow from Operations of $1.222 Billion
• Adjusted EBITDA (non-GAAP) Sequential Increase of 10% to $951 Million
• Delivered Strong Organic Growth1 (non-GAAP) in Bausch + Lomb/International Segment and Salix Business
• Expects to Exceed $5 Billion Debt Reduction Commitment Early
• Updates 2017 Full-Year Revenue Guidance Range and Maintains 2017 Full-Year Adjusted EBITDA (non-GAAP) Guidance

GUIDANCE:

Valeant Pharma Maintains FY2017 EPS of $3.60-$3.75. Valeant Pharma sees FY2017 revenue of $8.7-8.9 billion from $8.90 - $9.10 billion.

For earnings history and earnings-related data on Valeant Pharma (VRX) click here.